Studies on paclitaxel-loaded glyceryl monostearate nanoparticles

References

• Danino D, Talmon Y, Zana R. Vesicle-to-micelle transformation in systems containing dimeric surfactants. J Colloid Interface Sci 1997; 185: 84–93
   PubMed Web of Science ®Google Scholar
• Fidler IJ. Selection of successive tumor lines for metastasis. Nat (new bio) 1973; 242: 148–149
   PubMed Web of Science ®Google Scholar
• Freitas C, Muller RH. Stability determination of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte. J Microencapsulation 1999; 16: 59–71
   PubMed Web of Science ®Google Scholar
• Giacomo F, Laura M, Domenico S, Gennara C, Gaetano G. Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity. Drug Deliv 2005; 12: 385–392
   PubMed Web of Science ®Google Scholar
• Gregory R, DeLisa AF. Paclitaxel: A new antineoplastic agent for refractory ovarian cancer. Clin Pharm 1993; 12: 401–415
   PubMedGoogle Scholar
• Gude RP, Binda MM, Prasas HL, Andres JP, Klein-Santo R, Bonfil D. Studies on mechanisms responsible for inhibition of experimental metastasis of B16F10 murine melanoma by Pentoxifyline. J Biomed Sci 1996; 6: 133–141
   Google Scholar
• Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Meth 1989; 119: 203–210
   PubMed Web of Science ®Google Scholar
• Heiati H, Phillips NC, Tawashi R. Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride. Pharm Res 1996; 13: 1406–1410
   PubMed Web of Science ®Google Scholar
• Jong-Ho K, Yoo-Shin K, Sungwon K, Jae HP, Kwangmeyung K, Kuiwon C, et al. Hydrophobically modified glycol chitosan nanoparticles as carriers for Paclitaxel. J Contr Rel 2006; 111: 228–234
   PubMed Web of Science ®Google Scholar
• Kingston DGI. The chemistry of Taxol. Pharmacol Ther 1991; 52: 1–34
   PubMed Web of Science ®Google Scholar
• Korsenmeyer RW, Gurny R, Doelkar E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983; 15: 23–25
   Google Scholar
• Lilenbaum RC, Green MR. Novel chemotherapeutic agents in the treatment of non-small cell lung cancer. J Clin Oncol 1993; 11: 1391–1402
   PubMed Web of Science ®Google Scholar
• Martin V. Overview of paclitaxel (Taxol). Semin. Oncol. Nurs. 1993; 9: 2–5
   PubMedGoogle Scholar
• Mazzo D, Nguyen Huu JJ, Pagniez S, Denis P. Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. Am J Health-Syst Pharm 1997; 54: 566–569
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55–63
   PubMed Web of Science ®Google Scholar
• Muller RH, Maassen S, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) as potential carrier for human use: Interaction with human granulocytes. J Contr Rel 1997; 47: 261–269
   Web of Science ®Google Scholar
• Muller RH, Maassen S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996; 4: 161–170
   PubMed Web of Science ®Google Scholar
• Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161–177
   PubMed Web of Science ®Google Scholar
• Onetto N, Canett R, Winograd B, Catane R, Cougan M, Grechko J. Overview of taxol safety. J Natl Cancer Inst Monographs 1993; 15: 131–139
   Google Scholar
• Porter CJH, Moghimi SM, Illum L, Davis SS. The polyoxyethylene/polyoxypropylene block co-polymer poloxamer 407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett 1992; 305: 62–66
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19: 646–662
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mehnert W, Lucks JS, Muller RH. Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery. I. Production, Characterization and Sterilization. J. Control. Release 1994; 30: 83–96
   Web of Science ®Google Scholar
• Serpe L, Catalano MG, Cavalli R, Ugazio E, Bosco O, Canaparo R, et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 2004; 58: 673–680
   PubMed Web of Science ®Google Scholar
• Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002; 235: 179–192
   PubMed Web of Science ®Google Scholar
• Spencer CM, Faulds D. Paclitaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48: 782–794
   Google Scholar
• Stolnik S, Illum L, Davis SS. Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 1995; 16: 195–214
   Web of Science ®Google Scholar
• Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by mononuclear Pphagocyte system. Adv Drug Deliv Rev 1995; 17: 31–48
   Web of Science ®Google Scholar
• Subramanian N, Murthy RSR. Use of electrolyte induced flocculation technique for an in vitro steric stability study of steric stabilized liposome formulations. Pharmazie 2003; 59: 74–76
   Web of Science ®Google Scholar
• Thipgen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A gynaecologic oncology group study. J Clin Oncol 1994; 12: 1748–1753
   PubMed Web of Science ®Google Scholar
• Videira M, Florindo HF, Gouveia LF, Lobato MR, Almeida AJ. Triglyceride nanoparticles as potential carriers for Paclitaxel. 15th International Symposium on Microencapsulation. ParmaItaly 18–21 September, 2005
   Google Scholar
• Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Contr Rel 1997; 48: 223–236
   Web of Science ®Google Scholar
• Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999a; 16: 751–757
   PubMed Web of Science ®Google Scholar
• Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenous injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Contr Rel 1999b; 59: 299–307
   PubMed Web of Science ®Google Scholar
• Yuan H, Miao J, Du Y-Z, You J, Hu F-Q, Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm 2008; 348: 137–145
   PubMed Web of Science ®Google Scholar